What is LimFlow?
LimFlow is a privately held, venture-backed entity dedicated to transforming the treatment landscape for chronic limb-threatening ischemia. This condition, increasingly prevalent due to factors like diabetes, heart disease, kidney disease, and an aging population, often leaves patients facing major amputation as a last resort. LimFlow's minimally invasive system is engineered to bypass blocked arteries in the leg and restore oxygenated blood flow to the foot through the venous system. This intervention aims to resolve chronic pain, enhance quality of life, facilitate wound healing, and crucially, prevent the need for major limb amputation for many patients.
How much funding has LimFlow raised?
LimFlow has raised a total of $73.5M across 2 funding rounds:
Series C
$33.5M
Series D
$40M
Series C (2018): $33.5M with participation from Sofinnova Partners, Balestier, Bpifrance, and The French Sovereign investment bank
Series D (2022): $40M led by Soleus Capital and Longitude Capital
Key Investors in LimFlow
Soleus Capital
Soleus Capital is a healthcare investment firm specializing in innovative life sciences sectors, including biotech and medtech, investing across the healthcare lifecycle to advance cutting-edge solutions.
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology, medical technology, and health solutions companies, aiming to scale innovations and improve patient care.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability, actively partnering with entrepreneurs to develop transformative innovations.
What's next for LimFlow?
The recent major strategic investment signals a pivotal growth phase for LimFlow, likely enabling the company to accelerate its commercialization efforts, expand its market reach, and potentially invest further in research and development for its CLTI treatment system. This infusion of capital, following substantial prior funding rounds, positions LimFlow to address a significant unmet need in vascular intervention and solidify its market presence.
See full LimFlow company page
